Menu

Venture Deep Dives: Prescription Digital Therapeutics

Learn how PDTs could disrupt the $534B pharmaceutical industry

Doctor digital network overlay
Written by

Peter MacEwan

Published on

Read

2 min

In this series, we hone in on a specific element of venture capital with one of our investing experts.

Today I want to recommend our Deep Dive on Prescription Digital Therapeutics presented by Green D’s Managing Partner, Laura Bordewieck Rippy. Laura has served as a serial CEO, Chairman, Board Member, Advisor, and Executive in high-tech companies. Her experience spans consumer to enterprise, mobile to fintech, SaaS to eCommerce, seed to Fortune 50.

Watch Laura’s Deep Dive into Prescription Digital Therapeutics

See video policy below.

Laura’s deep dive into prescription digital therapeutics (PDTs) is an eye-opening examination of an entirely new prescription treatment market that has recently emerged and gained strong momentum during pandemic-era lockdowns. Popular mobile applications such as Headspace and Noom allow users to develop mindfulness and adopt weight loss regimens, respectively, all from their smart devices and in the comfort of their own homes.

As the research and development costs of traditional medications and treatments climb, doctors and clinicians are increasingly turning to PDTs to help improve patient outcomes without the financial cost. Laura’s research puts the PDT market at roughly $6-7 billion, making this pharmaceutical industry disruptor a compelling venture investment opportunity.

I hope this presentation shows you how PDTs have immense potential not just for the end users whose health benefits from them, but the potential these therapeutics have to disrupt the wider pharmaceutical industry.

Want to learn more?
View all our available funds and secure data rooms, or schedule an intro call.

New to AV?
Sign up and access exclusive venture content.

Contact [email protected] for additional information. To see additional risk factors and investment considerations, visit av-funds.com/disclosures.

Written by

Peter MacEwan

Peter has startup experience in both the nonprofit and business sectors, a BA from Wesleyan University, and an MBA from The Wharton School. Peter developed expertise building teams and strategic planning in the San Francisco Bay Area, driving growth across multiple seed- and early-stage companies (with many nights spent as informal adviser to a network of entrepreneurs). Peter has a passion for social impact and loves working with people who love what they do and strive to get better at it.

LinkedIn
Tagged with

Follow us

AV Headquarters
670 N. Commercial Street
Suite 403
Manchester, NH 03101
General inquiries: [email protected]

Press inquiries: [email protected]

603-518-8112

Follow us

Neither Alumni Ventures nor any of its funds are sponsored by, affiliated with, or otherwise endorsed by any university. For further details see our Legal & Privacy Policy.

Video Policy: By consuming this content I acknowledge that I may be considering an investment with AV funds for my own or my client’s account. I agree that information contained herein may not be relied upon or used for any other purpose. Offers to purchase securities are only made through formal offering documents, which describe risks (which are significant), terms, and other important information that must be considered before an investment decision is made. To see Important Disclosure Information, visit: https://av-funds.com/disclosures.

Testimonial/Endorsement Policy: Testimonials/Endorsements were provided by the participants without compensation, but each participant has a relationship with Alumni Ventures (AV) from which they benefit. All views expressed are the individual’s own and do not represent the experience of all AV fund investors or companies in which AV funds invest. Please note that testimonials are no guarantee of future performance or success. Any provider of an endorsement that is affiliated with a portfolio company Alumni Ventures has received investment funding from AV, and may in the future seek and/or receive additional funding from AV. This circumstance constitutes a conflict of interest. Providers of testimonials or endorsements were not chosen at random or according to any objective basis, but rather on the basis of their relationship with AV.

Investor Portal Update Policy: Investor portfolio data is updated once per quarter in the AV Investor Portal.

Alumni Ventures is America’s largest VC firm for individual investors based on the combination of total capital raised, number of investments, and number of investors of leading VC firms as reported by Pitchbook and other publicly available information reviewed by AV.

(1) Internal Rate of Return (IRR) for AV Funds is net of management fees and incentive allocations applied to amounts distributed to investors, and gross of incentive allocations applicable to unrealized gains on investments held by AV Funds. IRR for AV Funds includes uninvested cash, unrealized investments, and amounts distributed to investors. The IRR shown for the Russell 2000 indices are gross of fees because indices are not managed investments, and it is not possible to invest directly in an index. For additional information see av-funds.com/disclosures. All investment involves risk, including risk of loss. Past performance is not necessarily indicative of future results. For more information on AV Funds’ investment returns, please see here.

To see additional risk factors and investment considerations, visit: https://av-funds.com/disclosures

© 2024, Alumni Ventures. All rights reserved.